<DOC>
	<DOCNO>NCT02608697</DOCNO>
	<brief_summary>The purpose placebo-controlled , double-blind study assess effect several dose CAT-2054 LDL-C hypercholesterolemic patient stable dose high-intensity statin , evaluate safety tolerability different dose CAT-2054 4 week .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy CAT-2054 Combination With Atorvastatin Patients With Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Between 18 74 year Screening Hypercholesterolemia ( LDLC ≥ 70 mg/dL &lt; 190 mg/dL ) plus stable dose statin least 4 week prior Screening Satisfies one following : 1 . Female patient childbearing potential must use appropriate highly effective contraception ( regimen result failure rate &lt; 1 % per year ) partner 4 week prior Screening , remain compliant treatment phase 4 week last dose investigational product 2 . Male patient must use acceptable highly effective contraceptive method treatment phase 4 week last dose investigational product Body mass index ( BMI ) ≤45 kg/m2 History major cardiovascular event ( stroke , TIA , MI , PTCI , CABG , hospitalization due heart failure ) within 6 month Screening Type I diabetes mellitus use insulin Active peptic ulcer disease history muscle disease myopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>